# Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

> **NCT03555565** · — · COMPLETED · sponsor: **Takeda** · enrollment: 1026 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Alogliptin and Metformin hydrochloride

## Key facts

- **NCT ID:** NCT03555565
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 1026 (ACTUAL)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555565, "Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03555565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*